Drug Trial Radar · NCT03908970
Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome
Last checked: Nov 19, 2026Latest source record: Jan 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
364
Actual
Start
Mar 25, 2019
Primary completion
Dec 28, 2019
Study completion Dec 28, 2019
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.Otsuka
- Sponsor type
- Industry
- First posted
- Apr 9, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 15 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To demonstrate the superiority of IMP (1% OPA-15406 ointment or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in Investigator's Global Assessment (IGA) at Week 4 as the primary endpoint in adult patients with AD.
Conditions
- Atopic Dermatitis
Interventions
1% OPA-15406Drug
Twice daily
PlacebosDrug
Twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Responder Rate of Investigator's Global Assesment(IGA) of Disease SeverityTime frame: At Week 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kitago Hifuka Clinic
Sapporo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.